Lexaria's DehydraTECH Shows Enhanced Brain Delivery of Semaglutide in Preclinical Study
Lexaria Bioscience's drug delivery technology demonstrated improved brain distribution of GLP-1 drug semaglutide in rodents, potentially leading to better safety and efficacy for weight loss treatments.
Lexaria Bioscience Corp. has reported successful results from a preclinical study showing its DehydraTECH technology enhances brain biodistribution of semaglutide, the active ingredient in GLP-1 weight loss drugs. The study found that DehydraTECH-processed semaglutide achieved higher brain concentrations than conventional formulations, with the 5mg DehydraTECH composition outperforming the 15mg Rybelsus equivalent composition in brain fluorescence signal intensity.
The research involved fluorescently tagged semaglutide administered to Sprague Dawley rats, with detailed imaging revealing enhanced distribution in key brain regions including the brainstem, hypothalamus, and circumventricular organs. These areas are critical for semaglutide's mechanism of action in regulating appetite and energy expenditure. John Docherty, Lexaria President and CSO, noted that previous rodent studies with other DehydraTECH-processed compounds have shown superior safety and efficacy, suggesting similar benefits could apply to GLP-1 drugs.
Enhanced brain delivery of GLP-1 drugs could address significant limitations in current treatments. Semaglutide works through direct and indirect activation of GLP-1 receptors in brain nuclei that control food intake, reward pathways, and energy expenditure. Improved brain biodistribution may enable better appetite suppression while potentially reducing common side effects like nausea, which affects many patients using current GLP-1 therapies. The study findings suggest that DehydraTECH technology could support improved pharmacodynamic performance through unique delivery enhancements.
The implications extend beyond immediate therapeutic benefits. As understanding grows that GLP-1 drug performance depends heavily on brain neurochemistry, technologies that improve brain delivery become increasingly valuable. Lexaria's results, while preliminary from a small pilot study, indicate potential for developing safer and more effective next-generation GLP-1 medications. The company considers these findings encouraging for additional research and potential industry partnerships aimed at optimizing GLP-1 drug formulations. The study was conducted by an independent animal research facility specializing in pharmacokinetic evaluations, though the small sample size limited statistical analysis.